Curi RMB Capital LLC Boosts Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Curi RMB Capital LLC grew its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 2.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 433,815 shares of the medical equipment provider's stock after acquiring an additional 11,882 shares during the period. Curi RMB Capital LLC owned about 0.94% of BioLife Solutions worth $11,262,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. State Street Corp increased its stake in shares of BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock valued at $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Geode Capital Management LLC increased its position in BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider's stock valued at $21,107,000 after buying an additional 18,473 shares in the last quarter. Barclays PLC raised its stake in BioLife Solutions by 20.1% during the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider's stock valued at $1,613,000 after buying an additional 10,803 shares during the last quarter. Proficio Capital Partners LLC bought a new stake in BioLife Solutions in the fourth quarter worth $638,000. Finally, Stifel Financial Corp grew its stake in shares of BioLife Solutions by 5.4% in the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock worth $325,000 after acquiring an additional 670 shares during the last quarter. Institutional investors own 93.24% of the company's stock.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, EVP Aby J. Mathew sold 1,597 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $39,925.00. Following the transaction, the executive vice president now directly owns 260,601 shares in the company, valued at approximately $6,515,025. This trade represents a 0.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sarah Aebersold sold 2,695 shares of BioLife Solutions stock in a transaction on Monday, March 17th. The stock was sold at an average price of $25.44, for a total transaction of $68,560.80. Following the transaction, the insider now owns 43,165 shares in the company, valued at $1,098,117.60. This represents a 5.88 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 72,127 shares of company stock valued at $1,676,533. 2.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BLFS shares. StockNews.com raised BioLife Solutions from a "sell" rating to a "hold" rating in a research report on Tuesday, April 8th. HC Wainwright lifted their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Finally, Northland Securities increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $31.17.

BioLife Solutions Stock Performance

NASDAQ:BLFS traded up $0.45 during mid-day trading on Thursday, reaching $24.80. The company's stock had a trading volume of 455,252 shares, compared to its average volume of 378,128. The firm's fifty day moving average price is $24.34 and its two-hundred day moving average price is $25.21. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock has a market cap of $1.18 billion, a P/E ratio of -23.40 and a beta of 1.93. BioLife Solutions, Inc. has a 12-month low of $16.10 and a 12-month high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.32. The business had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the previous year, the firm posted ($0.21) EPS. On average, equities analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.